Life Sciences Research for Lifelong Health

Rebecca Gilley

Becky Gilley (nee Ley) also comes from ‘‘south of the river’ but did her degree in Molecular Biology amongst the dark satanic mills at the University of Manchester. From there she moved back ‘darn sarf’ to Reading and did a PhD in Molecular Virology. She did her first post-doc at the Institute of Child Health, Great Ormond Street working on chromosome translocations, leukaemogenesis and T cell biology. She has worked in Simon’s group since 2002 making important contributions to understanding the role of ERK1/2 and ERK5 pathways in regulating gene expression, cell proliferation and cell survival. In addition, she provides core support in retroviral and letiviral expression systems and serves on the Institute Biological Safety Committee. Her favourite colour is Pink.

Latest Publications

RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence.

Galloway A, Saveliev A, Łukasiak S

Science (New York, N.Y.)
352 1095-9203:453-9 (2016)

PMID: 27102483

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

Lochhead PA, Clark J, Wang LZ

Cell cycle (Georgetown, Tex.)
15 1551-4005:506-18 (2016)

PMID: 26959608

Maternal DNA Methylation Regulates Early Trophoblast Development.

Branco MR, King M, Perez-Garcia V

Developmental cell
36 1878-1551:152-63 (2016)

PMID: 26812015

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.

Caunt CJ, Sale MJ, Smith PD

Nature reviews. Cancer
15 1474-1768:577-92 (2015)

PMID: 26399658

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.

Ashford AL, Dunkley TP, Cockerill M

Cellular and molecular life sciences : CMLS
1420-9071: (2015)

PMID: 26346493

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer.

Sale MJ, Cook SJ

Biochemical Society transactions
42 1470-8752:776-83 (2014)

PMID: 25109957